Can you discuss the definition, evaluation, and management of acute kidney injury (AKI)?

Acute Kidney Injury: Definition, Evaluation, and Management

Definition and Staging

AKI is defined by KDIGO criteria as an increase in serum creatinine ≥0.3 mg/dL within 48 hours, OR an increase ≥50% within 7 days, OR urine output <0.5 mL/kg/hour for 6 hours 1. This functional definition captures the acute decline in kidney function that distinguishes AKI from chronic kidney disease (CKD), which persists beyond 3 months 2.

Key Diagnostic Thresholds:

• Stage 1: SCr increase 1.5-1.9× baseline OR ≥0.3 mg/dL, OR urine output <0.5 mL/kg/hr for 6-12 hours
• Stage 2: SCr increase 2.0-2.9× baseline, OR urine output <0.5 mL/kg/hr for ≥12 hours
• Stage 3: SCr increase ≥3.0× baseline OR ≥4.0 mg/dL, OR urine output <0.3 mL/kg/hr for ≥24 hours, OR anuria for ≥12 hours, OR initiation of RRT 3, 4

The AKI-AKD-CKD Continuum:

AKI exists on a continuum with acute kidney disease (AKD) and CKD. AKD encompasses AKI plus kidney dysfunction or damage lasting <3 months but >7 days (GFR <60 mL/min/1.73m² for <3 months OR decrease in GFR ≥35% or SCr increase >50% for <3 months) 2, 1. This intermediate category recognizes that kidney injury often doesn't resolve within the traditional AKI timeframe and patients remain at elevated risk for progression to CKD 2.

Evaluation Approach

Initial Assessment - Focus on These Specific Elements:

Volume Status Determination:

• Assess for hypovolemia: orthostatic hypotension, dry mucous membranes, decreased skin turgor, tachycardia
• Assess for hypervolemia/congestion: elevated JVP, peripheral edema, pulmonary crackles, hepatojugular reflux
• Use point-of-care ultrasound to assess IVC diameter and collapsibility, venous congestion 5

Nephrotoxin Exposure:

• Immediately discontinue all nephrotoxic agents when possible 2: NSAIDs, aminoglycosides, vancomycin, contrast agents, ACE inhibitors/ARBs (in acute setting), calcineurin inhibitors
• Review drug dosing adjustments for renal elimination 2, 6

Urinalysis with Microscopy - Interpret as Follows:

• Muddy brown casts → acute tubular necrosis (ATN)
• RBC casts → glomerulonephritis or vasculitis
• WBC casts → acute interstitial nephritis or pyelonephritis
• Eosinophils → acute interstitial nephritis
• Proteinuria >3g/day → glomerular disease 6

Hemodynamic Assessment:

• Do not interpret mean arterial pressure in isolation - integrate with cardiac output, central venous pressure, right ventricular function, and intra-abdominal pressure 5
• Assess for cardiorenal syndrome: elevated CVP with low cardiac output
• Measure intra-abdominal pressure if abdominal compartment syndrome suspected

Biomarker Considerations:

Use cystatin C when serum creatinine is unreliable (extremes of muscle mass, liver disease, malnutrition) 5.

Consider structural damage biomarkers (TIMP-2, IGFBP7, NGAL, KIM-1) only when results will change management 5, 7 - specifically within an actionable response pathway such as triggering prevention bundles in high-risk patients 5. These biomarkers are not yet part of standard AKI classification but show promise for early detection 6, 7.

Referral Triggers:

Emergent nephrology consultation for:

• Stage 2 or 3 AKI 3
• Stage 1 AKI with decompensated comorbid condition 3
• Unclear etiology 3
• Suspected glomerulonephritis (consider kidney biopsy) 1

Management Strategy

Foundational Principles:

1. Address Underlying Cause:

• Treat sepsis aggressively with source control and antimicrobials
• Relieve urinary obstruction (postrenal AKI)
• Stop offending drugs in drug-induced AKI 6

2. Optimize Volume Status - Avoid Reflexive Fluid Loading:

Critical caveat: Do NOT automatically give fluids in response to oliguria 5. Instead:

• If hypovolemic: Resuscitate with balanced crystalloids (avoid 0.9% saline due to potential harm on kidney outcomes) 1
• If euvolemic: Maintain euvolemia, avoid both under- and over-resuscitation
• If hypervolemic/congested: Initiate diuretic therapy or consider ultrafiltration 1

Monitor for fluid overload - this is a critical inflection point where continued fluid administration becomes harmful. Use clinical assessment plus ultrasound for venous congestion 5.

3. Ensure Adequate Perfusion Pressure:

• Target MAP based on individual patient hemodynamics, not arbitrary thresholds 2
• Choose vasopressors based on hemodynamic phenotype - integrate cardiac output and venous pressure data 1
• Consider functional hemodynamic monitoring in complex cases 2

4. Nephrotoxin Stewardship:

• Discontinue nephrotoxic agents 2, 6
• Dose-adjust all renally eliminated medications 2, 6
• Regarding ACE-I/ARBs: Discontinue during acute AKI episode; timing of reinitiation requires individualized assessment based on clinical context (heart failure, post-surgical, sepsis) 1
• Avoid radiocontrast when alternatives exist 2

5. Metabolic Management:

• Avoid hyperglycemia 2
• Correct electrolyte disturbances (hyperkalemia, metabolic acidosis)
• Consider sodium bicarbonate for severe metabolic acidosis, though evidence is limited 1
• Optimize nutrition 3

Renal Replacement Therapy (RRT):

Initiate RRT based on urgent indications or trajectory-based criteria, NOT serum creatinine alone 5:

Urgent indications:

• Refractory hyperkalemia
• Severe metabolic acidosis
• Uremic complications (pericarditis, encephalopathy)
• Severe fluid overload unresponsive to diuretics
• Certain intoxications

Trajectory-based approach: Consider RRT when AKI is worsening despite optimal medical management, particularly in Stage 3 AKI with oliguria/anuria 5, 8.

The optimal timing, dose, and modality of RRT remain areas of active investigation 1. Individualize RRT decisions by aligning patient phenotype, risk trajectory, and organ support objectives 5.

Post-AKI Recovery and Follow-up

AKI survivors face substantial long-term risks: progression to CKD, cardiovascular events, rehospitalization, and death 7, 9.

Recovery planning should begin during hospitalization 5:

• Monitor for incomplete recovery (persistent AKD beyond 7 days) 2
• If AKD persists beyond 3 months, patient meets criteria for CKD and requires long-term nephrology follow-up 2
• Arrange post-discharge nephrology follow-up for Stage 2-3 AKI or incomplete recovery 9
• Counsel patients on CKD risk and need for ongoing monitoring 9

Common Pitfalls to Avoid:

1. Reflexive fluid administration for oliguria without volume assessment - can worsen outcomes in congested patients 5
2. Relying on MAP alone for perfusion assessment - must integrate hemodynamic parameters 5
3. Continuing nephrotoxic medications - systematic review required 2, 6
4. Using 0.9% saline for resuscitation - balanced crystalloids preferred 1
5. Initiating RRT based solely on creatinine threshold - use clinical trajectory and urgent indications 5
6. Inadequate post-discharge follow-up - AKI survivors need ongoing monitoring 9